Skip to main content
Signal8

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

$INCYPress releaseJun 13, 2026, 11:15 AM ETRead the release

Incyte presented positive Phase 1 data for INCA033989, a first-in-class mutCALR-targeted antibody, at the EHA 2026 Congress, showing rapid and durable clinical responses in patients with myelofibrosis and essential thrombocythemia. In essential thrombocythemia, 70% of patients achieved complete hematologic response with a median onset of ~2 weeks, while in myelofibrosis, the drug demonstrated significant spleen volume reductions and anemia improvements alongside consistent molecular activity.

Key figures

Drug Name
INCA033989
Phase Of Trial
Phase 1
Et chr rate
70%
Mf svr35 rate
39%
Et chr phr rate
87%
Et median time to chr
~2 weeks
Mf vaf reduction rate
89%
Mf anemia response rate
60%
Et patients on treatment
95%
Mf patients on treatment
84%
Et median response duration
23 weeks

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.